Work
I work across the full diagnostics continuum, from discovery and product development to investment, implementation and the institutional capabilities that sustain impact.
The common thread is translation: connecting evidence, decisions, capital, organisations and health systems.
Why diagnostics
Every clinical decision begins with a question. Is this cancer? Will this treatment work? Is the disease progressing? Can it be detected earlier? Diagnostics exist to answer those questions.
Precision medicine, oncology, transplantation, infectious disease, screening, public health and increasingly artificial intelligence all depend on accurate biological information arriving at the right time. Yet this underlying information layer remains one of the least understood and most strategically neglected parts of healthcare.
A connected practice
Diagnostic impact is not produced by any single stage. It depends on a sequence of scientific, clinical, regulatory, commercial and institutional decisions that must remain connected.
My perspective
My experience spans scientific discovery, product development, validation, regulation, commercialisation, investment evaluation, implementation and ecosystem building. That breadth shapes how I assess both individual opportunities and the systems around them.
My scientific career began in genomics, bioinformatics and translational research. Following doctoral and postdoctoral training in Portugal, the United Kingdom and the United States, I spent more than twelve years leading a computational genomics research group at the Instituto Gulbenkian de Ciência.
67+ publications · 9,550+ citations · h-index 39
View the scientific record →I helped establish Portugal’s first dedicated clinical oncogenomics company, introducing liquid-biopsy services when the technology was still largely absent from routine clinical practice in the country. I later founded and led Ophiomics through the journey from scientific concept to regulated precision-diagnostics products, including clinical validation, CE and UKCA marking, ISO 13485, manufacturing, fundraising, partnerships and international commercialisation.
Explore the founder’s journey →Having raised equity and non-dilutive funding, built ventures, reviewed opportunities and worked with investors and funders, I became increasingly interested in how diagnostic opportunities are evaluated and why conventional maturity measures often fail to capture their real risks.
Explore Diagnostics Readiness Levels →Diagnostics only matter when they influence decisions. Work with hospitals, laboratories, clinicians, health systems and translational programmes has reinforced a simple lesson: success depends not only on the technology, but on its fit with clinical workflows, procurement, reimbursement and healthcare infrastructure.
Beyond individual products lies a larger question: how do organisations, ecosystems and countries build diagnostic capability? My work has included building BioData.pt and its connection to ELIXIR, helping establish and lead Healthcare City, contributing to sector strategy through P-BIO, and developing work on translational infrastructure and diagnostics sovereignty.
Explore the sovereignty work →Where I work
These are overlapping areas rather than separate services. Each draws on experience across science, company building, investment, implementation and institutions.
Product strategy, validation, regulation, commercialisation and company building: connecting scientific promise to something clinicians, patients and markets can actually use.
Assessing scientific, clinical, regulatory, commercial and strategic readiness so that investors, funders and leadership teams can make better decisions.
Designing the programmes, partnerships, data infrastructure and industrial capabilities that allow innovation to move repeatedly from possibility to practice.
How I engage
Work usually begins with a specific opportunity, difficult decision or institutional ambition. The form of engagement follows the problem.
Current directions
Current work includes diagnostic opportunity evaluation, translational infrastructure and the industrial and institutional foundations of diagnostics sovereignty.
If you are working on a diagnostic opportunity, venture, investment decision or institutional challenge, the most useful starting point is a conversation about the problem.
Start a conversation